Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery

NCT02169284 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02169284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02169284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
October 1, 2014
Completion date
March 30, 2018
Enrollment
50 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, recurrent bladder carcinoma